Decibel expands global footprint with agreement to supply the UK market

CALGARY — Canadian-based Decibel Cannabis Company Inc., manufacturer of cannabis and extract products, has expanded its global footprint by entering into a supply agreement to provide premium dried medical cannabis flower to 4C LABS, a healthcare, technology, and pharmaceutical company focused on virtual prescribing, pharmaceutical distribution and clinical development in cannabis based medicinal products in the United Kingdom and Channel Islands.

“We are excited to partner with 4C LABS, a leading organization in the growing medical cannabis industry in the UK, that echoes Decibel’s commitment to quality and patient care. Not only will this unlock a strong partnership and a new market for Decibel’s craft cannabis products, it also sets the stage for further growth into other European markets,” said Adam Coates, Chief Revenue Officer. “Decibel’s success with Qwest flower products in Canada and in Israel’s medical market reinforces the demand for premium cannabis products and the reputation we have built to service that demand.”

Decibel will grant strain exclusivity of rare and unique cultivars to be distributed by 4C LABS
three-year supply agreement. The initial shipment is expected to be before year end.

“4C LABS is building a patient focused best-in-class product line for the UK & Channel Islands, the Qwest craft flower line strengthens the top end of the 4C LABS product offerings. Decibel’s innovative craft quality Qwest flower products will fill an empty segment in the UK market and bring a world class BC Cannabis product to UK patients,” said Greg Dobbin, CEO 4C LABS. “Decibel’s success in Canada, the most competitive cannabis market in the world, is a product of hard work, innovation and attention to detail, qualities that will resonate with UK patients.”